ARTICLE | Company News
Mitsubishi licenses MedImmune's ADC technology
September 24, 2015 1:48 AM UTC
The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) granted the Tanabe Research Laboratories (TRL) subsidiary of Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) an exclusive, worldwide license to its pyrrolobenzodiazepine (PBD)-based warhead and linker technology.
TRL will combine MedImmune's PBD technology with its own antibodies to develop next-generation monospecific and bispecific antibody-drug conjugates (ADCs) against several oncology targets. ...